Member Info for mazik

"We are delighted that the EPO has now formally granted the European Patent which is now validated across Europe. This achieves another key step in our IP strategy where we are also making excellent progress following the notice of allowance made recently by the CPO for the potentially huge market of China and the ongoing discussions in other key jurisdictions. We look forward to updating the market on these in due course."

Weak holders left the platform...onwards with lots of news in the pipeline, Read the interims to get the gist whats in front of us.

Nanjan a starter....20p plus from monday, when the news sinks in

Strategy remains the same as it always has and that is to generate sufficient proof of concept data with a view to attracting large pharma and biotech partners to enter into collaborations to explore using Nuvec(R) as their chosen delivery system. The issues facing mRNA Covid vaccines in respect of storage and distribution are well known following the Coronavirus pandemic. DNA vaccines are more stable than mRNA yet need to use a much higher dose due to the delivery systems currently chosen. Demonstrating suitable efficacy whilst addressing the storage and dosage issues would, we believe, greatly enhance Nuvec(R) as a potential delivery tool for vaccines in the eyes of collaborators.

The Company is also pleased to announce that it has been informed by the Chinese Patent Office ("CPO") of its intention to grant the Patent in China in relation to Nuvec(R)
Discussions with other key patent authorities in the US, Canada and India are continuing and updates will be provided by the Company on these in due course. Preparing for revival towards towards double figures IMO

Excellent Rns, Patent news is it revival

Nigel summed it up what is in front of us "strategy remains the same as it always has and that is to generate sufficient proof of concept data with a view to attracting large pharma and biotech partners to enter into collaborations to explore using Nuvec® as their chosen delivery system. The issues facing mRNA Covid vaccines in respect of storage and distribution are well known following the Coronavirus pandemic. DNA vaccines are more stable than mRNA yet need to use a much higher dose due to the delivery systems currently chosen. Demonstrating suitable efficacy whilst addressing the storage and dosage issues would, we believe, greatly enhance Nuvec® as a potential delivery tool for vaccines in the eyes of collaborators.
"With the short-term work programmes likely to provide plenty of data points over the next three to six months coupled with the ongoing MTA work we remain cautiously optimistic as we seek to commercialise Nuvec®. We continue to be well funded for all existing work streams and look forward to analysing the results of studies and sharing them with interested parties when they become available." Opinion before who they are working with assuming Evotec is also providing the data...my guess Astra Zieneca...we will no longer be a penny stock IMO

It should be more like 25p plus, two MTAs , Nuvec being assesed as jabs is going to be reality for Covid like flu jabs yearly...Big Brother will swipe while its cheap...not less than £500mcap...

Agree short termers out, glad held all and averaged to 25...original at 34p....few freefloat likely 20% of 125 million... good luck long termers

lakeside holding assumption is correct, most likely free float will be less than 40% of 125 million IMO. 30 years of trading never seen a manipulation at this scale...45k small holding in my ISA

Bargain at 16.55 that's what I got 19296 topup

Builder very true , a favour from them 19k top @ 16.45 in sell column....software is in error

Weak holders were robbed, time will tell imo

Positive buying from bargain hunters

Sterling increased in value from an average of $1.28 in the first half of 2020, which "partially offset the positive impact on revenues as a result of increased prices compared to H1 2020. Amazing SP from 37p to 16.5

Rerated soon , Cash over £12 million "This is part of a wider strategy to access the U.S. market and positions us well for further investigations of our lead asset in this devastating brain cancer as we continue to optimize SFX-01 for clinical trials and eventually partnering," Evgen Chief Executive Huw..... Wake up call soon IMO

Gained Orphan Drug designation for SFX-01 in the USA in a very short period of time. This is part of a wider strategy to access the US market and positions us well for further investigations of our lead asset in this devastating brain cancer as we continue to optimize SFX-01 for clinical trials and eventually partnering." Update soon FDA approval expected..

Very sad to hear about Andy as i have been on and off hear for the last three years.. May he rest in peace though as a Hur shareholder must have been painful...as he has missed its recovery...condolences to all his friends and most important his family..

Topped up 85k shares, cheap as chips

could be approval of hydrogen project from Surrey Council....35% up something cooking